Motilium Oral Suspension 5 mg/5 ml

Motilium Oral Suspension is a gastrointestinal medication containing Domperidone Maleate (5 mg/5 ml) manufactured by Ethical Drugs Limited. Priced at ৳35.00 per unit, this oral suspension addresses digestive disorders, nausea, and vomiting. It enhances gastric motility by blocking dopamine receptors without significant CNS effects.

This suspension treats dyspeptic symptoms like bloating, heartburn, and delayed stomach emptying. It’s effective for acute nausea from migraines, infections, or medications. In Parkinson’s patients, it counters drug-induced nausea. It also aids barium transfer in radiological studies by accelerating gastrointestinal transit.

Key pharmacological action: Domperidone increases lower esophageal sphincter pressure and gastric emptying. Unlike other dopamine antagonists, it minimally crosses the blood-brain barrier, reducing neurological side effects. Clinical studies show improved symptoms within 30 minutes of administration.

Dosage guidelines:

• Adults: 10–20 mg (10–20 ml suspension) every 6–8 hours before meals.
• Children: 0.2–0.8 mg/kg body weight, adjusted per condition. Maximum treatment duration: 12 weeks.

Store below 30°C, away from light/moisture. Avoid in pregnancy; safe during lactation.

Common side effects include dry mouth (1.9%), mild headaches (1.2%), and rare skin reactions (0.1%). Drug interactions with bromocriptine or MAO inhibitors require caution. No overdose cases reported, but supervise pediatric use closely.

For alternatives, explore Domperidone generics. Motilium’s fast-acting formula makes it a preferred oral suspension for digestive health in Bangladesh.

Adults: 10-20 mg (2-4 teaspoonfuls) 3-4 times daily before meals. Children: 0.2-0.4 mg/kg body weight. Dose reduction needed in hepatic/renal impairment. Maximum treatment duration 12 weeks.

Side-effects are rare; exceptionally some transient intestinal cramps have been reported. Extrapyramidal phenomena are rare in young children and exceptional in adults: they reverse spontaneously and completely as soon as the treatment is stopped. As the pituitary gland is located outside the blood-brain barrier, domperidone may induce an increase in the plasma prolactin level. In rare case this hyperprolactinaemia may give rise to neuroendocrinological phenomena such as galactorrhoea and gynaecomastia. When the blood-brain barrier is immature (as in infants) or impaired, the possible occurrence of neurological side-effects cannot be totally excluded. Rare allergic reactions, such as rash and urticaria, have also been reported.

Pregnancy Category C. Compatible with breastfeeding—low milk excretion. Monitor infant for side effects.

High neurological risk in infants. Hepatic patients require dose adjustment. Monitor prolactin levels during prolonged use. Store in cool dry place as directed by Ethical Drugs Limited.

Pediatric: Avoid below 1 year. Geriatric: Assess renal function. Hepatic impairment: Max 10 mg/dose. Renal failure: Extend dosing intervals.

Symptoms of overdosage may include drowsiness, disorientation and extrapyramidal reactions, especially in children. In case of overdosage, the administration of activated charcoal, and close observation of the patients are recommended. Anticholinergic, antiparkinson drugs or antihistamines with anticholinergic properties may be helpful in controlling the extrapyramidal reactions.